Claims for RU <strong>486</strong>/PG Abortion18 per cent out of 116 women (nine per cent after RU <strong>486</strong>administration <strong>and</strong> nine per cent after PG (Swahn <strong>and</strong>Bygdeman, 1989); to 15.3 per cent out of 2,040 women(Silvestre et al., 1990). Figures for nausea range from 57 percent of 70 women (Somell <strong>and</strong> Ölund, 1990) [this is the meanfigure of women experiencing nausea complications in boththe failure <strong>and</strong> the success group, since the studydifferentiates]; to 25 per cent of 100 women (Hill et al., 1990a:414). Figures for diarrhea range from 13 per cent out of 579women (UK Multicentre Trial); to 8.2 per cent of 97 women(Zheng, 1989).For regimens using RU <strong>486</strong> without PG analogues,gastrointestinal effects remain significant, despite the claimsthat it is the addition of PGs which promotes thesecomplications. Zheng, who combined nausea <strong>and</strong> vomitingstatistics cites 40 per cent out of 95 women who experienceboth (Zheng, 1989). Grimes reports vomiting as occurringin 14 per cent of those who aborted <strong>and</strong> in 60 per cent ofthose women who did not abort Figures for nausea rangefrom 27 per cent of 124 women (Sitruk-Ware et al., 1990); to24 per cent of 100 women (Couzinet et al., 1986). Diarrheais not a frequent complication after RU <strong>486</strong> administrationunaccompanied by prostagl<strong>and</strong>in analogues.If the reader is confused, it is because the studies areconfusing. One impression, however, is prevalent.Gastrointestinal complications, <strong>and</strong> the range of such, aresignificant The complications of vomiting <strong>and</strong> nausea seemunrelated to PGs, whereas diarrhea is mostly linked to PGadministration in the combination treatment. Cameron et al.,(1986), for example, report a low incidence of diarrhea withRU <strong>486</strong> alone (one per cent of 20 women).Other immediate complications associated with chemicalabortions are fainting (4.8 per cent in Sitruk-Ware et al.,1990); <strong>and</strong> fatigue (61.3 per cent in Sitruk-Ware et al., 1990).1990). Li et al. report a 23 per cent shift in mood change,manifesting itself as irritability <strong>and</strong> depression. They also45
RU <strong>486</strong>report one case of marked thirst sensation. They thusconclude that the findings in their study demonstrate thatRU <strong>486</strong> ‘affected the various functions of the hypothalamus’(Li et al., 1988; see also Chapter Three).Finally, Sitruk-Ware et al. cite the use of antibiotics bothbefore <strong>and</strong> after vacuum aspiration with women who hadincomplete abortions. They report that 25 per cent of the 28women in their study who had incomplete abortions alsodeveloped a fever (Sitruk-Ware et al., 1990). The questionneeds to be asked how many women who had incompleteabortions in other studies developed infections <strong>and</strong> fever<strong>and</strong> required antibiotics.Promoters of RU <strong>486</strong>/PG abortions emphasize their lowpercentage of complications. As we have demonstrated, thisis not true. However, even where complications are of lowincidence, in terms of percentages, it is important to ask howmany women we are talking about. One percent of 579women—the percent of women receiving blood transfusionin the UK Multicentre Trial—does in fact mean five women.Although too few women to acquire statistical significance,there is another st<strong>and</strong>ard we should employ here. Five womenis five too many women. More critically, the number ofwomen who might require transfusions in places where thereis no medical backup to stop the bleeding <strong>and</strong> administer atransfusion could be significantly larger.Ultimately, we must highlight the number of drugs thatare now part of the chemical abortion treatment regimenbecause we view this as another complication. Nowhere hasthis melange of drugs been acknowledged. In light of theclaims made that RU <strong>486</strong> is a simple, pill-popping methodof abortion, we highlight the complexity, in cumulativefashion, of what has now become a drug cocktail.In the beginning, there was:46
- Page 2 and 3:
Renate Klein is Lecturer in Women
- Page 4 and 5: RU 486Misconceptions,Myths and Mora
- Page 6 and 7: ACKNOWLEDGEMENTSWe would like to ex
- Page 8 and 9: CONTENTSINTRODUCTION 1CHAPTER ONETh
- Page 10 and 11: INTRODUCTIONInitial euphoria greete
- Page 12 and 13: IntroductionUnfortunately, objectio
- Page 14 and 15: Introductiondo not know or do not a
- Page 16 and 17: Introductionused widely for years a
- Page 18 and 19: CHAPTER ONEThe History of RU 486RU
- Page 20 and 21: The History of RU 486consultants ar
- Page 22 and 23: The History of RU 486Events in Fran
- Page 24 and 25: The History of RU 486service of wom
- Page 26 and 27: The History of RU 486The result app
- Page 28 and 29: The History of RU 486developing cou
- Page 30 and 31: The History of RU 486University Hos
- Page 32 and 33: The History of RU 486pharmacovigila
- Page 34 and 35: CHAPTER TWOClaims for RU 486/PG Abo
- Page 36 and 37: Claims for RU 486/PG Abortionsevera
- Page 38 and 39: Claims for RU 486/PG Abortionthe Br
- Page 40 and 41: Claims for RU 486/PG Abortionan imm
- Page 42 and 43: Claims for RU 486/PG Abortionby the
- Page 44 and 45: Claims for RU 486/PG Abortionby the
- Page 46 and 47: Claims for RU 486/PG Abortionfrom A
- Page 48 and 49: Claims for RU 486/PG Abortioncommen
- Page 50 and 51: Claims for RU 486/PG AbortionSome s
- Page 52 and 53: Claims for RU 486/PG Abortionbreeze
- Page 56 and 57: Claims for RU 486/PG Abortion1. RU
- Page 58 and 59: Claims for RU 486/PG AbortionRU 486
- Page 60 and 61: Claims for RU 486/PG Abortionwider
- Page 62 and 63: Claims for RU 486/PG Abortionmedica
- Page 64 and 65: Claims for RU 486/PG Abortionreligi
- Page 66 and 67: What Is RU 486 and How Does It Work
- Page 68 and 69: What Is RU 486 and How Does It Work
- Page 70 and 71: What Is RU 486 and How Does It Work
- Page 72 and 73: What Is RU 486 and How Does It Work
- Page 74 and 75: What Is RU 486 and How Does It Work
- Page 76 and 77: What Is RU 486 and How Does It Work
- Page 78 and 79: What Is RU 486 and How Does It Work
- Page 80 and 81: What Is RU 486 and How Does It Work
- Page 82 and 83: What Is RU 486 and How Does It Work
- Page 84 and 85: What Is RU 486 and How Does It Work
- Page 86 and 87: What Is RU 486 and How Does It Work
- Page 88 and 89: What Is RU 486 and How Does It Work
- Page 90 and 91: The Role of Prostaglandins: Known a
- Page 92 and 93: The Role of Prostaglandins: Known a
- Page 94 and 95: The Role of Prostaglandins: Known a
- Page 96 and 97: The Role of Prostaglandins: Known a
- Page 98 and 99: The Role of Prostaglandins: Known a
- Page 100 and 101: The Role of Prostaglandins: Known a
- Page 102 and 103: The Role of Prostaglandins: Known a
- Page 104 and 105:
The Role of Prostaglandins: Known a
- Page 106 and 107:
The Role of Prostaglandins: Known a
- Page 108 and 109:
The Role of Prostaglandins: Known a
- Page 110 and 111:
The Role of Prostaglandins: Known a
- Page 112 and 113:
The Role of Prostaglandins: Known a
- Page 114 and 115:
The Role of Prostaglandins: Known a
- Page 116 and 117:
The Role of Prostaglandins: Known a
- Page 118 and 119:
The Role of Prostaglandins: Known a
- Page 120 and 121:
The Role of Prostaglandins: Known a
- Page 122 and 123:
ConclusionInstead, Baulieu uses the
- Page 124 and 125:
Conclusionintervention. Thus, RU 48
- Page 126 and 127:
Conclusionbetween population contro
- Page 128 and 129:
ConclusionThis article, appearing i
- Page 130 and 131:
Conclusion‘a whole net of relatio
- Page 132 and 133:
ENDNOTESChapter One1The paten t lic
- Page 134 and 135:
Endnotes12The Journal Officiel publ
- Page 136 and 137:
Endnotesin Gynecology and Obstetric
- Page 138 and 139:
Endnotesof menses. On the third day
- Page 140 and 141:
EndnotesAnother such example is the
- Page 142 and 143:
Bibliographyand Segal, Sheldon (Eds
- Page 144 and 145:
Bibliographyprostaglandin F 2•. A
- Page 146 and 147:
BibliographyDelaney, Anne. (1991, 2
- Page 148 and 149:
Bibliographyresponses to the steroi
- Page 150 and 151:
Bibliographyabnormalities resulting
- Page 152 and 153:
Bibliographyprogesterone receptor b
- Page 154 and 155:
BibliographyOdlind, Viveca and Birg
- Page 156 and 157:
BibliographyBinding of the anti-pro
- Page 158 and 159:
BibliographyUlmann, André, Teutsch
- Page 160:
Bibliographytermination by vacuum a